Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $20

Benzinga · 1d ago
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $17 to $20.